Trial Profile
Peptide Vaccination in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Patients With Unresectable Stage III or IV Malignant Melanoma A Phase I Study (First in Man)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs IO 102 (Primary) ; Ipilimumab (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; First in man
- 19 Oct 2017 New trial record